Rate My Professor Paul Griffin

Griffin's research specializations lie in infectious diseases, vaccine development, antimalarial therapies, and pathogen detection. He chairs the Advanced Training Committee in Infectious Diseases for the Royal Australasian College of Physicians, which oversees training for specialists in Australia, and is a director and scientific advisory board member of the Immunisation Coalition, contributing to vaccine education and advocacy. Key publications include 'Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study' (2025, The Lancet Infectious Diseases); 'Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose' (2024, The Lancet Infectious Diseases); 'Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine' (2020, The New England Journal of Medicine); chapters in Kucers’ The Use of Antibiotics on niclosamide, furazolidone, and diloxanide furoate (2017 and 2010 editions); and 'Safety and reproducibility of a clinical trial system using induced blood-stage Plasmodium vivax infection' (2016, PLoS Neglected Tropical Diseases). He has emerged as a trusted national media spokesperson on infectious diseases, microbiology, vaccines, and the COVID-19 pandemic, appearing on programs such as The Project, Sunrise, Today Show, A Current Affair, CTV Canada, and BBC.